GI Dynamics Release: New Data Presented At EASD Demonstrate Robust Cardiometabolic Health Effects Of Endobarrier® Therapy In Obese People With And Without Diabetes

LEXINGTON, Mass. & SYDNEY--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced new data demonstrating clinically meaningful improvements in the prevalence of metabolic syndrome, as well as a reduction in 10-year cardiovascular (CV) risk in obese patients treated with EndoBarrier® Therapy. Robert J. Chilton, D.O., F.A.C.C., professor, Department of Medicine, Division of Cardiology, University of Texas Health Science Center at San Antonio, presented these findings during a poster presentation at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.

Help employers find you! Check out all the jobs and post your resume.